GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

Nova Scotia physicians and other sexual health experts are calling on the provincial government to fund birth control and increase access to a medication used to prevent HIV.

The US Department of Health and Human Services is reinstating more than 450 employees at the Centers for Disease Control and ...

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Last week, Montaner, who also heads the HIV/AIDS program at St. Paul’s Hospital and is the chair of AIDS research at UBC and ...

America’s HIV epidemic is stubborn, but a new telemedicine service is shifting the narrative. According to HIV.gov, about 1.2 ...

SAN FERNANDO City, La Union (PIA)— A 500 percent increase in reported human immunodeficiency virus (HIV) cases in the country ...

WASHINGTON — The Trump administration has reversed the firings of hundreds of staffers at the Centers for Disease Control and ...

Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...

The National Agency for the Control of AIDS (NACA) says sit has inaugurated the Prevention of Mother to Child Transmission ...